Treatment for Co-Occurring Stimulant and Opioid Use Disorders
Howell B, Lin L, Coughlin L. Treatment for Co-Occurring Stimulant and Opioid Use Disorders. JAMA Psychiatry 2024, 81: 853-854. PMID: 38985457, DOI: 10.1001/jamapsychiatry.2024.1775.Peer-Reviewed Original ResearchPostrelease Risk of Overdose and All-Cause Death Among Persons Released From Jail or Prison: Minnesota, March 2020-December 2021.
Hill K, Bodurtha P, Winkelman T, Howell B. Postrelease Risk of Overdose and All-Cause Death Among Persons Released From Jail or Prison: Minnesota, March 2020-December 2021. American Journal Of Public Health 2024, 114: 913-922. PMID: 39024534, PMCID: PMC11306622, DOI: 10.2105/ajph.2024.307723.Peer-Reviewed Original ResearchConceptsOverdose deathsPrison exposureJailPrisonRisk of overdoseRates of overdose deathsOverdose death ratesOpioid use disorderGeneral populationDeath recordsDrug overdosePeopleStandardized mortality ratioPersonsIncarcerationUse disorderPostreleaseMortality ratioDeath rateRisk of deathRetrospective cohort studyMortality riskCohort studyMinnesotaOverdoseW80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. W80 Buprenorphine-Naloxone vs. Extended-Release Naltrexone for Opioid Use Disorder in People With Recent Criminal Legal Involvement: A Secondary Analysis of the X:BOT Randomized Controlled Trial. Drug And Alcohol Dependence 2024, 260: 110698. DOI: 10.1016/j.drugalcdep.2023.110698.Peer-Reviewed Original ResearchBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiers